



ASX / MEDIA RELEASE

COCHLEAR BOARD CHANGES

Cochlear Limited Chairman Mr Tommie Bergman today announced the following changes to the Board.

Professor Brian Anderson AO has announced his decision to retire at the October 2005 AGM. Professor Anderson AO joined the Board prior to Cochlear's listing on the ASX in 1995 and has been an integral part of Cochlear's growth and development over that period.

Mr Donal O'Dwyer and Mr Paul Bell will be appointed to the Board effective 1st August 2005.

Mr O'Dwyer has over 20 years experience in the medical device industry. Between 2000 and 2004, he was worldwide president of Cordis Cardiology, one of Johnson & Johnson's medical device business units with turnover of over USD 2 billion. He is chairman of Atcor Medical and a director of Sunshine Heart Inc, Mesoblast Ltd and Angioblast Systems Inc.

Mr Bell has had an extensive executive career spanning over 30 years with the international pharmaceutical company Merck & Co Inc. Mr Bell was appointed as Managing Director of Australia in 1988 and from 1997 – 2002 was President of the Asia Pacific Human Health Division and a member of the global Merck Management Committee. Mr Bell is a director of Bio-Link Partners Ltd and GroPep Ltd.

Commenting on the changes, Mr Bergman said "We will miss Professor Anderson's input and know-how. He has made a significant contribution to Cochlear's development from a small listed company in 1995 to its current position.

"Both Mr O'Dwyer and Mr Bell bring extensive international experience in relevant fields to the Cochlear Board. I am delighted to have secured the services of two such experienced business executives and look forward to their contributions to the growth and strategic development of Cochlear Limited".

For further information contact:

Dr Chris Roberts, CEO
Neville Mitchell, CFO/Company Secretary
Ph: (02) 9428 6555

21 July 2005